Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumours 1Metastatic Pancreatic Ductal Adenocarcinoma 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
SLC-0111 × Clear all
NCT03450018 2024-05-24

SLC-0111-17-01

British Columbia Cancer Agency

Phase 1/2 Terminated
6 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT02215850 2016-05-17

Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours

Welichem Biotech Inc.

Phase 1 Completed
24 enrolled
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡